Regeneron Says Muscular Disorder Treatment Livsayis Gets FDA Approval

Dow Jones07:31
 
 

Regeneron Pharmaceuticals said the Food and Drug Administration has approved Livsayis as a treatment for certain adult patients suffering from generalized myasthenia gravis.

The condition is an autoimmune muscular disorder which can result in weakened muscles, trouble breathing, and altered vision, among other symptoms. The Myasthenia Gravis Foundation of America said a 2021 study estimated that 37 out of every 100,000 people in the U.S. have myasthenia gravis.

Livsayis, or cemdisiran, is a small interfering RNA therapeutic that reduces levels of circulating C5 protein, limiting terminal complement activation, a key driver of the disease, the company said. Regeneron added Livsayis is its first approved siRNA therapy and neurology medicine.

Livsayis is the first and only approved siRNA therapy in generalized myasthenia gravis and the only FDA-approved treatment for the condition administered subcutaneously four times a year, according to Regeneron.

 
 

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment